Evidence map›Paper›PMID 25395992›Full record

ArticleLung cancer management2014

Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Timothy F Burns, Laura P Stabile

Abstract read
In one paragraph

Article in Lung cancer management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Sex-specificity in Surgical Stages of Lung Cancer in Young Adults.The open respiratory medicine journal · 2023
    Article
  8. Role of sex hormones in lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2021
    Review
  9. Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Timothy F BurnsDepartment of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, Hillman Cancer Center Research Pavilion, 2.18e, 5117 Centre Avenue, Pittsburgh, PA 15213-1863, USA.
Laura P StabileDepartment of Pharmacology & Chemical Biology, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 441, 5117 Centre Avenue, Pittsburgh, PA 15213-1863, USA.

Funding

Vitamin D3 Modulation of Inflammation and Lung Cancer RiskP50CA090440 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DACIC, SANJA · 2001 to 2015
$34.6M
NCI NIH HHS P50 CA090440
6 · The paper itself

Abstract

The estrogen signaling pathway is involved in the biology of non-small-cell lung cancer and represents a novel therapeutic target for lung cancer. This is supported by epidemiological evidence, preclinical studies and recent data from clinical trials. Antiestrogens and inhibitors of estrogen synthesis have been shown to inhibit lung tumor growth as well as prevent lung tumorigenesis in preclinical models both

Identifiers

PMID25395992
PMCPMC4226441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.